Clinical Trial Update: Immunogenicity of GSKs' MMR Vaccine (209762) vs. M-M-R® II, When Given With Routine Vaccines at 12-15 Months of Age [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the immunogenicity of GSK's MMR vaccine (209762) compared with M-M-R II when co-administered with routine vaccines at 12-15 months; com…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Measles
• Mumps
• Rubella

Drugs mentioned

• GSK's MMR vaccine (209762)
• M-M-R II (Measles, Mumps, and Rubella Vaccine)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Rubella, Mumps | Phase 2 | Status: COMPLETED | Results posted: 2011-11-04